Ross D Hannan

List of Publications by Year
in descending order

108 papers	8,963 citations	30070 54 h-index	43889 91 g-index
112 all docs	112 docs citations	112 times ranked	11610 citing authors

#	Article	IF	Citations
1	Targeting RNA Polymerase I with an Oral Small Molecule CX-5461 Inhibits Ribosomal RNA Synthesis and Solid Tumor Growth. Cancer Research, 2011, 71, 1418-1430.	0.9	482
2	Inhibition of RNA Polymerase I as a Therapeutic Strategy to Promote Cancer-Specific Activation of p53. Cancer Cell, 2012, 22, 51-65.	16.8	468
3	The reninâ€"angiotensin system and cancer: old dog, new tricks. Nature Reviews Cancer, 2010, 10, 745-759.	28.4	438
4	mTOR-Dependent Regulation of Ribosomal Gene Transcription Requires S6K1 and Is Mediated by Phosphorylation of the Carboxy-Terminal Activation Domain of the Nucleolar Transcription Factor UBFâ€. Molecular and Cellular Biology, 2003, 23, 8862-8877.	2.3	390
5	ATRX interacts with H3.3 in maintaining telomere structural integrity in pluripotent embryonic stem cells. Genome Research, 2010, 20, 351-360.	5.5	343
6	Centromere RNA is a key component for the assembly of nucleoproteins at the nucleolus and centromere. Genome Research, 2007, 17, 1146-1160.	5.5	255
7	An Immediate Response of Ribosomal Transcription to Growth Factor Stimulation in Mammals Is Mediated by ERK Phosphorylation of UBF. Molecular Cell, 2001, 8, 1063-1073.	9.7	226
8	AKT induces senescence in human cells via mTORC1 and p53 in the absence of DNA damage: implications for targeting mTOR during malignancy. Oncogene, 2012, 31, 1949-1962.	5.9	221
9	The nucleolus: an emerging target for cancer therapy. Trends in Molecular Medicine, 2013, 19, 643-654.	6.7	205
10	Coordinate regulation of ribosome biogenesis and function by the ribosomal protein S6 kinase, a key mediator of mTOR function. Growth Factors, 2007, 25, 209-226.	1.7	204
11	Targeting the nucleolus for cancer intervention. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 802-816.	3.8	198
12	Direct Actions of Urotensin II on the Heart. Circulation Research, 2003, 93, 246-253.	4.5	196
13	Dysregulation of the basal RNA polymerase transcription apparatus in cancer. Nature Reviews Cancer, 2013, 13, 299-314.	28.4	187
14	UBF levels determine the number of active ribosomal RNA genes in mammals. Journal of Cell Biology, 2008, 183, 1259-1274.	5.2	171
15	MAD1 and c-MYC regulate UBF and rDNA transcription during granulocyte differentiation. EMBO Journal, 2004, 23, 3325-3335.	7.8	166
16	A Novel Mouse Model of Atherosclerotic Plaque Instability for Drug Testing and Mechanistic/Therapeutic Discoveries Using Gene and MicroRNA Expression Profiling. Circulation Research, 2013, 113, 252-265.	4.5	164
17	Adenoviral-Directed Expression of the Type 1A Angiotensin Receptor Promotes Cardiomyocyte Hypertrophy via Transactivation of the Epidermal Growth Factor Receptor. Circulation Research, 2002, 90, 135-142.	4.5	159
18	Cardiac hypertrophy: A matter of translation. Clinical and Experimental Pharmacology and Physiology, 2003, 30, 517-527.	1.9	133

#	Article	IF	Citations
19	First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study. Cancer Discovery, 2019, 9, 1036-1049.	9.4	129
20	Second AKT: The rise of SGK in cancer signalling. Growth Factors, 2010, 28, 394-408.	1.7	127
21	AKT Promotes rRNA Synthesis and Cooperates with c-MYC to Stimulate Ribosome Biogenesis in Cancer. Science Signaling, 2011, 4, ra56.	3.6	126
22	Expression, Regulation and Putative Nutrient-Sensing Function of Taste GPCRs in the Heart. PLoS ONE, 2013, 8, e64579.	2.5	121
23	Rb and p130 regulate RNA polymerase I transcription: Rb disrupts the interaction between UBF and SL-1. Oncogene, 2000, 19, 4988-4999.	5.9	119
24	Dysregulation of RNA polymerase I transcription during disease. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2013, 1829, 342-360.	1.9	116
25	The nucleolus as a fundamental regulator of the p53 response and a new target for cancer therapy. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2015, 1849, 821-829.	1.9	105
26	Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma. Cancer Discovery, 2016, 6, 59-70.	9.4	105
27	The role of UBF in regulating the structure and dynamics of transcriptionally active rDNA chromatin. Epigenetics, 2009, 4, 374-382.	2.7	100
28	Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signaling. Oncotarget, 2016, 7, 49800-49818.	1.8	93
29	Translational control of c-MYC by rapamycin promotes terminal myeloid differentiation. Blood, 2008, 112, 2305-2317.	1.4	92
30	CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer. Nature Communications, 2020, 11, 2641.	12.8	90
31	c-MYC coordinately regulates ribosomal gene chromatin remodeling and Pol I availability during granulocyte differentiation. Nucleic Acids Research, 2011, 39, 3267-3281.	14.5	88
32	A Specific Role for AKT3 in the Genesis of Ovarian Cancer through Modulation of G2-M Phase Transition. Cancer Research, 2006, 66, 11718-11725.	0.9	85
33	Urotensin II Promotes Hypertrophy of Cardiac Myocytes via Mitogen-Activated Protein Kinases. Molecular Endocrinology, 2004, 18, 2344-2354.	3.7	84
34	RNA polymerase I transcription in confluent cells: Rb downregulates rDNA transcription during confluence-induced cell cycle arrest. Oncogene, 2000, 19, 3487-3497.	5.9	81
35	Regulation of rDNA transcription in response to growth factors, nutrients and energy. Gene, 2015, 556, 27-34.	2.2	79
36	Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population. Blood, 2017, 129, 2882-2895.	1.4	74

#	Article	IF	Citations
37	Autophagy Induction Is a Tor- and Tp53-Independent Cell Survival Response in a Zebrafish Model of Disrupted Ribosome Biogenesis. PLoS Genetics, 2013, 9, e1003279.	3.5	73
38	AKT-independent PI3-K signaling in cancer – emerging role for SGK3. Cancer Management and Research, 2013, 5, 281.	1.9	73
39	Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors. European Journal of Cancer, 2013, 49, 3936-3944.	2.8	72
40	Ribosomal DNA copy loss and repeat instability in ATRX-mutated cancers. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 4737-4742.	7.1	72
41	Affinity Purification of Mammalian RNA Polymerase I. Journal of Biological Chemistry, 1998, 273, 1257-1267.	3.4	70
42	Overexpression of the transcription factor UBF1 is sufficient to increase ribosomal DNA transcription in neonatal cardiomyocytes: implications for cardiac hypertrophy.. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 8750-8755.	7.1	69
43	Widespread FRA1-Dependent Control of Mesenchymal Transdifferentiation Programs in Colorectal Cancer Cells. PLoS ONE, 2014, 9, e88950.	2.5	69
44	The long noncoding RNA lncNB1 promotes tumorigenesis by interacting with ribosomal protein RPL35. Nature Communications, 2019, 10, 5026.	12.8	67
45	Conditional Inactivation of Upstream Binding Factor Reveals Its Epigenetic Functions and the Existence of a Somatic Nucleolar Precursor Body. PLoS Genetics, 2014, 10, e1004505.	3.5	66
46	Targeting RNA polymerase I to treat MYC-driven cancer. Oncogene, 2015, 34, 403-412.	5.9	66
47	Regulation of Ribosomal DNA Transcription during Contraction-induced Hypertrophy of Neonatal Cardiomyocytes. Journal of Biological Chemistry, 1996, 271, 3213-3220.	3.4	65
48	Identification of a mammalian RNA polymerase I holoenzyme containing components of the DNA repair/replication system. Nucleic Acids Research, 1999, 27, 3720-3727.	14.5	64
49	Urotensin II: the old kid in town. Trends in Endocrinology and Metabolism, 2004, 15, 175-182.	7.1	64
50	Cross talk between corticosteroids and alpha-adrenergic signalling augments cardiomyocyte hypertrophy: A possible role for SGK1. Cardiovascular Research, 2006, 70, 555-565.	3.8	60
51	Combined inhibition of PI3K-related DNA damage response kinases and mTORC1 induces apoptosis in MYC-driven B-cell lymphomas. Blood, 2013, 121, 2964-2974.	1.4	59
52	The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer. Clinical Cancer Research, 2016, 22, 5539-5552.	7.0	59
53	The mTORC1 Inhibitor Everolimus Prevents and Treats EÎ¼-<i>Myc</i> Lymphoma by Restoring Oncogene-Induced Senescence. Cancer Discovery, 2013, 3, 82-95.	9.4	58
54	Expression of Constitutively Active Angiotensin Receptors in the Rostral Ventrolateral Medulla Increases Blood Pressure. Hypertension, 2006, 47, 1054-1061.	2.7	57

#	Article	IF	Citations
55	Palbociclib synergizes with BRAF and MEK inhibitors in treatment naÃ¯ve melanoma but not after the development of BRAF inhibitor resistance. International Journal of Cancer, 2018, 142, 2139-2152.	5.1	56
56	Targeting RNA polymerase I transcription and the nucleolus for cancer therapy. Expert Opinion on Therapeutic Targets, 2013, 17, 873-878.	3.4	55
57	Unravelling the molecular complexity of <scp>GPCR</scp>â€mediated <scp>EGFR</scp> transactivation using functional genomics approaches. FEBS Journal, 2013, 280, 5258-5268.	4.7	53
58	A novel role for the Pol I transcription factor UBTF in maintaining genome stability through the regulation of highly transcribed Pol II genes. Genome Research, 2015, 25, 201-212.	5.5	52
59	Regulation of rDNA Transcription Factors during Cardiomyocyte Hypertrophy Induced by Adrenergic Agents. Journal of Biological Chemistry, 1995, 270, 8290-8297.	3.4	48
60	Adenovirus-mediated delivery of relaxin reverses cardiac fibrosis. Molecular and Cellular Endocrinology, 2008, 280, 30-38.	3.2	48
61	Perturbations at the ribosomal genes loci are at the centre of cellular dysfunction and human disease. Cell and Bioscience, 2014, 4, 43.	4.8	47
62	Targeting the nucleolus for cancer-specific activation of p53. Drug Discovery Today, 2014, 19, 259-265.	6.4	40
63	A functional genetic screen defines the AKT-induced senescence signaling network. Cell Death and Differentiation, 2020, 27, 725-741.	11.2	40
64	What?s new in the renin-angiotensin system?. Cellular and Molecular Life Sciences, 2004, 61, 2695-2703.	5.4	37
65	Combined Angiotensin and Endothelin Receptor Blockade Attenuates Adverse Cardiac Remodeling Post-Myocardial Infarction in the Rat: Possible Role of Transforming Growth Factor Î²1. Journal of Molecular and Cellular Cardiology, 2001, 33, 969-981.	1.9	36
66	Proliferation of Neointimal Smooth Muscle Cells after Arterial Injury. Journal of Biological Chemistry, 2004, 279, 42221-42229.	3.4	36
67	Signaling to the ribosome in cancerâ€"It is more than just mTORC1. IUBMB Life, 2011, 63, 79-85.	3.4	35
68	Cardiovascular role of urotensin II: effect of chronic infusion in the rat. Peptides, 2004, 25, 1783-1788.	2.4	34
69	Selective inhibition of RNA polymerase I transcription as a potential approach to treat African trypanosomiasis. PLoS Neglected Tropical Diseases, 2017, 11, e0005432.	3.0	34
70	Inositol Polyphosphate 1-Phosphatase Is a Novel Antihypertrophic Factor. Journal of Biological Chemistry, 2002, 277, 22734-22742.	3.4	33
71	Drosophila Ribosomal Protein Mutants Control Tissue Growth Non-Autonomously via Effects on the Prothoracic Gland and Ecdysone. PLoS Genetics, 2011, 7, e1002408.	3.5	31
72	Expression of c-fos and Related Genes in the Rat Heart in Response to Norepinephrine. Journal of Molecular and Cellular Cardiology, 1993, 25, 1137-1148.	1.9	30

#	Article	IF	Citations
73	The RNA Polymerase I Transcription Factor UBF Is the Product of a Primary Response Gene. Journal of Biological Chemistry, 1995, 270, 4209-4212.	3.4	30
74	A functional siRNA screen identifies genes modulating angiotensin II-mediated EGFR transactivation. Journal of Cell Science, 2013, 126, 5377-90.	2.0	30
75	Adrenergic agents, but not triiodo-L-thyronine induce c-fos and c-myc expression in the rat heart. Basic Research in Cardiology, 1991, 86, 154-164.	5.9	29
76	Hfp inhibits<i>Drosophila myc</i>transcription and cell growth in a TFIIH/Hay-dependent manner. Development (Cambridge), 2010, 137, 2875-2884.	2.5	28
77	Cellular regulation of ribosomal DNA transcription:both rat and Xenopus UBF1 stimulate rDNA transcription in 3T3 fibroblasts. Nucleic Acids Research, 1999, 27, 1205-1213.	14.5	27
78	Determination of the Exact Molecular Requirements for Type 1 Angiotensin Receptor Epidermal Growth Factor Receptor Transactivation and Cardiomyocyte Hypertrophy. Hypertension, 2011, 57, 973-980.	2.7	27
79	A 19S proteasomal subunit cooperates with an ERK MAPK-regulated degron to regulate accumulation of Fra-1 in tumour cells. Oncogene, 2012, 31, 1817-1824.	5.9	27
80	Implications of EpithelialÃ¢â,¬â€œMesenchymal Plasticity for Heterogeneity in Colorectal Cancer. Frontiers in Oncology, 2015, 5, 13.	2.8	27
81	Self-reverting mutations partially correct the blood phenotype in a Diamond Blackfan anemia patient. Haematologica, 2017, 102, e506-e509.	3.5	26
82	The RNA polymerase I transcription inhibitor CX-5461 cooperates with topoisomerase 1 inhibition by enhancing the DNA damage response in homologous recombination-proficient high-grade serous ovarian cancer. British Journal of Cancer, 2021, 124, 616-627.	6.4	26
83	Tackling the EGFR in pathological tissue remodelling. Pulmonary Pharmacology and Therapeutics, 2006, 19, 74-78.	2.6	25
84	PR55Î±-containing protein phosphatase 2A complexes promote cancer cell migration and invasion through regulation of AP-1 transcriptional activity. Oncogene, 2015, 34, 1333-1339.	5.9	21
85	Clustered somatic mutations are frequent in transcription factor binding motifs within proximal promoter regions in melanoma and other cutaneous malignancies. Oncotarget, 2016, 7, 66569-66585.	1.8	21
86	<scp>AKT</scp> signalling is required for ribosomal <scp>RNA</scp> synthesis and progression of <scp>E</scp>Î¼â€<i>Myc </i><scp>B</scp>â€cell lymphoma <i>inÂvivo</i>. FEBS Journal, 2013, 280, 5307-5316.	4.7	19
87	Glucocorticoids improve erythroid progenitor maintenance and dampen <i>Trp53</i> response in a mouse model of Diamondâ€“Blackfan anaemia. British Journal of Haematology, 2015, 171, 517-529.	2.5	18
88	Migration of Small Ribosomal Subunits on the 5â€² Untranslated Regions of Capped Messenger RNA. International Journal of Molecular Sciences, 2019, 20, 4464.	4.1	17
89	A novel small molecule that kills a subset of MLL-rearranged leukemia cells by inducing mitochondrial dysfunction. Oncogene, 2019, 38, 3824-3842.	5.9	17
90	Cardiac hypertrophy in vivo is associated with increased expression of the ribosomal gene transcription factor UBF. FEBS Letters, 2003, 548, 79-84.	2.8	16

#	Article	IF	Citations
91	A phospho-proteomic screen identifies novel S6K1 and mTORC1 substrates revealing additional complexity in the signaling network regulating cell growth. Cellular Signalling, 2011, 23, 1338-1347.	3.6	16
92	Relative Expression Levels Rather Than Specific Activity Plays the Major Role in Determining<i>In Vivo</i>AKT Isoform Substrate Specificity. Enzyme Research, 2011, 2011, 1-18.	1.8	16
93	Defining the essential function of FBP/KSRP proteins:<i>Drosophila</i>Psi interacts with the mediator complex to modulate<i>MYC</i>transcription and tissue growth. Nucleic Acids Research, 2016, 44, 7646-7658.	14.5	16
94	S6 Kinase is essential for MYC-dependent rDNA transcription in Drosophila. Cellular Signalling, 2015, 27, 2045-2053.	3.6	15
95	rDNA Chromatin Activity Status as a Biomarker of Sensitivity to the RNA Polymerase I Transcription Inhibitor CX-5461. Frontiers in Cell and Developmental Biology, 2020, 8, 568.	3.7	15
96	Suppression of ABCE1-Mediated mRNA Translation Limits N-MYCâ€“Driven Cancer Progression. Cancer Research, 2020, 80, 3706-3718.	0.9	15
97	Effect of Dominant-Negative Epidermal Growth Factor Receptors on Cardiomyocyte Hypertrophy. Journal of Receptor and Signal Transduction Research, 2006, 26, 659-677.	2.5	14
98	Cell cycle and growth stimuli regulate different steps of RNA polymerase I transcription. Gene, 2017, 612, 36-48.	2.2	14
99	Defective Hfp-dependent transcriptional repression of dMYC is fundamental to tissue overgrowth in Drosophila XPB models. Nature Communications, 2015, 6, 7404.	12.8	13
100	CX-5461 Sensitizes DNA Damage Repairâ€“proficient Castrate-resistant Prostate Cancer to PARP Inhibition. Molecular Cancer Therapeutics, 2021, 20, 2140-2150.	4.1	9
101	Amino acid-dependent signaling via S6K1 and MYC is essential for regulation of rDNA transcription. Oncotarget, 2016, 7, 48887-48904.	1.8	8
102	Combining High-Content Imaging and Phenotypic Classification Analysis of Senescence-Associated Beta-Galactosidase Staining to Identify Regulators of Oncogene-Induced Senescence. Assay and Drug Development Technologies, 2016, 14, 416-428.	1.2	8
103	Genome wide mapping of UBF binding-sites in mouse and human cell lines. Genomics Data, 2015, 3, 103-105.	1.3	6
104	Unexpected role of CDK4 in a G2/M checkpoint. Cell Cycle, 2015, 14, 1351-1352.	2.6	5
105	Hfp, the Drosophila homolog of the mammalian<i>c-myc</i>transcriptional-repressor and tumor suppressor FIR, inhibits<i>dmyc</i>transcription and cell growth. Fly, 2011, 5, 129-133.	1.7	3
106	Inhibition of Pol I Transcription a New Chance in the Fight Against Cancer. Technology in Cancer Research and Treatment, 2017, 16, 736-739.	1.9	3
107	Emerging Role of the Urotensin II System in Cardiovascular Disease. Cardiology, 2003, 3, 153-158.	0.3	2
108	AngiotensinII mediates cardiomyocyte hypertrophic growth pathways via MMP-dependent HB-EGF liberation. International Journal of Peptide Research and Therapeutics, 2003, 10, 431-435.	0.1	1